Table 1.
Baseline characteristics
| Parameter | Total (N = 21) |
|---|---|
| n (%) | |
| Median age (range), years | 74 (55–82) |
| Sex | |
| Female | 10 (48%) |
| Male | 11 (52%) |
| Smoking history | |
| Current smokers | 11 (52%) |
| Former smokers | 9 (43%) |
| Never smokers | 1 (5%) |
| Pulmonary disease at baseline | |
| COPD | 8 (38%) |
| Interstitial lung disease | 0 (0%) |
| Tumor stage | |
| Stage IIIb | 2 (10%) |
| Stage IIIc | 2 (10%) |
| Stage IV | 17 (81%) |
| Histology | |
| Adenocarcinoma | 14 (67%) |
| Squamous cell carcinoma | 6 (29%) |
| NSCLC not otherwise specified | 1 (5%) |
| PD-L1 status | 21 (100%)a |
| Dyspnea at baseline (according to NCI CTCAE) | |
| Grade 2 | 5 (24%) |
| Grade 3 | 7 (33%) |
| Liver metastases | |
|
No Yes |
18 (86%) 3 (14%) |
| Brain metastases | |
| No | 18 (86%) |
| Yes | 3 (14%) |
| Previous radiotherapy | |
| Brain | 1 (5%) |
| Lung | 1 (5%) |
| Mediastinum | 1 (5%) |
| Bone | 1 (5%) |
| Supraclavicular region | 1 (5%) |
NSCLC, nonsmall-cell lung cancer
aBy local testing (Ventana SP142 excluded). A confirmatory central PD-L1 testing (no data at this timepoint) by the Ventana SP263 assay will be performed